Advanced Enzyme Technologies Limited (ADVENZYMES)
₹267.00 +1.56% last close, 16 Oct
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Advanced Enzyme's revenue was ₹190 Cr (+2.1% year on year, -6.7% on the previous quarter), and net profit ₹38.6 Cr (-4.6% year on year); the operating margin was 26.9%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹190 | +2.1% | -6.7% |
| Operating profit | ₹51.0 | -9.7% | -19.4% |
| Net profit | ₹38.6 | -4.6% | -14.7% |
| EPS (₹) | 3.31 | -7.3% | -13.8% |
| Operating margin | 26.9% | — | — |
ADVENZYMES delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 53.91% of the ADVENZYMES shares traded on NSE were taken to delivery, against the stock's own 20-session average of 58.43%. That is close to its usual level.
Delivery in the last 5 sessions: 49.4% · 64.4% · 67.5% · 63.1% · 53.9%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Advanced Enzyme Technologies has received requests dated October 15, 2026, from four promoter group members to reclassify into the public category under Regulation 31A of SEBI LODR. The applicants collectively hold 25,000 equity shares, representing approximately 0.02% of the company's total equity base. The members stated they do not participate in management decisions or exercise control, having received shares via gifts. The proposed reclassification is subject to approval from the Board of Directors, shareholders, and stock exchanges.
- Requests received on October 15, 2026, from 4 promoter group members
- Jayesh Madhusudan Soni and Shruti Sharad Dhamdhere hold 10,000 shares (0.01%) each
- Dhanyakumar Kishor Gadiya holds 5,000 shares (0.00%) and Payal Akshay Kulkarni holds Nil shares
- Total shares seeking reclassification stand at 25,000 shares (~0.02% of equity)
- Subject to approval by Board of Directors, stock exchanges, and applicable SEBI LODR conditions
Advanced Enzyme Technologies Limited received requests from two promoter group members, Sunil Ramdayal Attal and Megha Jhawar, seeking reclassification to the 'Public' category under Regulation 31A of SEBI LODR. Together, they hold 9,000 equity shares, representing approximately 0.01% of the company's total equity base. Both individuals indicated they received the shares as gifts, hold no management or board roles, and exercise zero control over company decisions. The reclassification is subject to approval from the Board of Directors, stock exchanges, and compliance with statutory conditions.
- Sunil Ramdayal Attal holds 1,000 equity shares (0.00%) and requested reclassification to the Public category
- Megha Jhawar holds 8,000 equity shares (0.01%) and requested reclassification to the Public category
- Combined shareholding seeking reclassification stands at 9,000 shares (approx 0.01%)
- Requests were dated October 06, 2026, and received by the company on October 12, 2026
Advanced Enzyme Technologies Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The certificate was issued by Registrar and Share Transfer Agent MUFG Intime India Private Limited on October 03, 2026. It confirms that securities received for dematerialisation during the period were properly processed, confirmed/rejected, and listed on stock exchanges within prescribed timelines. This is a standard quarterly administrative compliance filing with no impact on business operations or financials.
- Compliance certificate filed for the quarter ended September 30, 2026
- Issued by RTA MUFG Intime India Private Limited dated October 03, 2026
- Submission to NSE and BSE completed on October 09, 2026 under Regulation 74(5)
Advanced Enzyme Technologies has extinguished 8,88,296 equity shares of face value Rs 2 each, which were bought back via the open market in September 2026. This brings total shares extinguished under the ongoing buyback program to 17,13,324 shares. Following this extinguishment on October 05, 2026, the company's paid-up share capital decreased from 11,11,51,122 shares (Rs 22.23 crore) to 11,02,62,826 shares (Rs 22.05 crore). The total shares extinguished so far represent roughly 1.53% of the pre-buyback share base.
- Extinguished 8,88,296 equity shares bought back from open market during September 2026
- Paid-up share capital reduced to Rs 22,05,25,652 across 11,02,62,826 shares
- Cumulative shares extinguished under the buyback reach 17,13,324 shares (8,25,028 prior + 8,88,296 current)
- Extinguishment processed via CDSL effective October 05, 2026
Advanced Enzyme Technologies has extinguished 8,25,028 equity shares of face value ₹2 each, bought back through the open market route during August 2026. The debit was confirmed by CDSL on September 02, 2026, pursuant to SEBI Buy-Back Regulations. The buyback was carried out under the public announcement dated August 10, 2026.
- Extinguishment of 8,25,028 equity shares of face value ₹2 each
- Shares were acquired via the open market route during August 2026
- CDSL debit executed on September 02, 2026
- Extinguishment certified by Practicing Company Secretary on September 07, 2026
Advanced Enzyme Technologies has received formal requests dated September 02, 2026, from 5 promoter group entities seeking reclassification to the 'Public' category under Regulation 31A of SEBI LODR Regulations. All five applicants—Savita Chandrakumar Rathi, Piyush Chandrakumar Rathi, Radhika Ashish Pujara, Advenza Global Limited, and Atharva Green Ecotech LLP—hold nil shares (0.00%) in the company. The reclassification is subject to approval from the Board of Directors and the stock exchanges, with zero direct impact on the company's existing shareholding structure or operations.
- 5 promoter group members requested reclassification to the Public category
- All 5 outgoing entities currently hold NIL equity shares (0.00% holding)
- Requests were received by the company on September 04, 2026
- Process remains subject to Board of Directors and stock exchange approvals
Advanced Enzyme Technologies reported Q1 FY27 consolidated revenue of ₹189.8 Cr (+2% YoY, -7% QoQ) and PAT of ₹38.6 Cr (-5% YoY, -15% QoQ), impacted by a timing-related sales reversal of ₹10 Cr. EBITDA margins contracted to 27% (down from 30% in Q1 FY26) due to higher power and fuel costs and product mix shifts. Growth was driven by Specialized Manufacturing (+41% YoY) and Bioprocessing (+30% YoY), while Human Healthcare fell 7% YoY. The Board also approved an open-market buyback of up to ₹69.7 Cr at a ceiling price of ₹500 per share and the acquisition of the remaining 4.28% stake in JC Biotech for ₹7.98 Cr.
- Q1 FY27 consolidated revenue rose 2% YoY to ₹189.8 Cr, impacted by a ₹10 Cr revenue reversal.
- EBITDA dropped 10% YoY to ₹51.0 Cr with EBITDA margin declining to 27% vs 30% YoY.
- Board approved a share buyback of up to ₹69.7 Cr at a maximum price of ₹500 per share via open market.
- Acquired remaining 4.28% stake in JC Biotech for ₹7.98 Cr, making it a 100% wholly-owned subsidiary.
Advanced Enzyme Technologies has approved a share buyback of up to ₹69.7 crore through the open market route. The maximum buyback price is set at ₹500 per share, representing a significant premium of approximately 66.7% over the current market price of ₹299.9. The company is mandated to utilize at least 75% of the buyback size (₹52.275 crore). This buyback represents 9.99% of the company's standalone paid-up capital and free reserves as of March 31, 2026.
- Maximum buyback size of ₹69.7 crore, capped at 9.99% of standalone net worth.
- Maximum buyback price of ₹500 per share, a 58.7% premium over the closing price of ₹314.95 on August 1, 2026.
- Minimum utilization requirement of 75% of the buyback size, totaling ₹52.275 crore.
- Indicative maximum of 1,394,000 shares to be bought back, representing 1.24% of total paid-up equity.
- The buyback will be conducted via the open market route on BSE and NSE over a period of up to 66 working days.
Advanced Enzyme Technologies has made the audio recording of its Q1 FY27 earnings call available to the public following the results for the quarter ended June 30, 2026. The call, held on August 12, 2026, provides management's perspective on the company's performance, which includes a TTM revenue of Rs 2,419 Cr and a robust ROCE of 24.0%. This disclosure is a standard transparency measure under SEBI Regulation 30. Investors can access the recording on the company's website to understand the strategy behind their 400+ proprietary products.
- Audio recording of the conference call held on August 12, 2026, is now available for public access.
- The call discussed the unaudited financial results for the quarter ended June 30, 2026.
- Company maintains a total fermentation capacity of 500 cubic meters across 9 manufacturing facilities.
- Management continues to target a 15% CAGR revenue growth through specialized manufacturing and US market penetration.
Advanced Enzyme Technologies has formally approved a buyback of equity shares for an aggregate amount not exceeding ₹69.7 crore. The maximum buyback price is set at ₹500 per share, representing a significant premium of approximately 67% over the current market price of ₹298.3. The buyback will be conducted via the open market route, excluding promoters, and represents 9.99% of the company's standalone net worth. The company is legally obligated to utilize at least 75% of the maximum buyback size, amounting to ₹52.275 crore.
- Maximum buyback size of ₹69.7 crore, representing 9.99% of standalone paid-up capital and free reserves.
- Maximum buyback price of ₹500 per share, a 58.7% premium over the closing price prior to the board meeting intimation.
- Indicative maximum of 1,394,000 shares to be bought back, which is 1.24% of the total paid-up equity.
- Minimum utilization requirement of 75% of the buyback size, totaling ₹52.275 crore.
- Buyback to be funded entirely through internal accruals and liquid surplus, which was ₹546 crore as per recent filings.
Advanced Enzyme Technologies has announced a share buyback from the open market for a maximum value of Rs 69.7 crore. The maximum buyback price is set at Rs 500 per share, representing a significant premium over the current market price of Rs 298.3. The company intends to utilize at least 75% of the maximum size (Rs 52.275 crore) for this purpose. The buyback is scheduled to open on August 14, 2026, and will conclude by November 20, 2026, or earlier if the maximum size is reached.
- Maximum buyback size of Rs 69.7 crore, representing 5.09% of consolidated net worth.
- Maximum buyback price of Rs 500 per share, a ~67% premium to the current price of Rs 298.3.
- Minimum buyback size commitment of Rs 52.275 crore (75% of maximum size).
- Indicative maximum of 1,394,000 shares to be repurchased, approximately 1.25% of total paid-up capital.
- Buyback period starts on August 14, 2026, and ends by November 20, 2026.
Advanced Enzyme Technologies reported a weak Q1 FY27 with consolidated PAT declining 5% YoY to ₹38.6 Cr and 15% sequentially. While revenue grew marginally by 2% YoY to ₹189.8 Cr, EBITDA margins contracted significantly to 27% from 30% in the previous year. The core Human Nutrition segment (60% of revenue) saw a 7% YoY decline, which was partially offset by strong growth in Specialized Manufacturing (+41%) and Industrial Bio-processing (+30%). Geographically, growth in Asia (+37%) was countered by a 4% decline in the domestic Indian market.
- Consolidated revenue grew 2% YoY to ₹189.8 Cr, but declined 7% on a sequential basis.
- EBITDA de-grew by 10% YoY to ₹51.0 Cr, with margins contracting to 27% from 30% in Q1 FY26.
- Specialized Manufacturing segment outperformed with 41% YoY growth, reaching ₹20.0 Cr.
- Human Nutrition segment revenue fell 7% YoY to ₹113.9 Cr, contributing 60% of total sales.
- Liquid surplus of ₹54.6 Cr maintained for potential inorganic acquisitions and R&D investment.
Advanced Enzyme Technologies reported a modest 2% YoY revenue growth at ₹189.8 Cr for Q1 FY27, but faced significant margin pressure. EBITDA declined 10% YoY to ₹51 Cr, with margins contracting to 27% from 30% in the year-ago period. The decline was primarily driven by a 7% drop in the core Human Nutrition segment due to lower Pharma/API sales. While Bio-Processing and Specialized Manufacturing grew 30% and 41% respectively, they were insufficient to maintain overall profitability levels, leading to a 5% YoY decline in PAT to ₹38.6 Cr.
- Consolidated Revenue grew 2% YoY to ₹1,898 million, but declined 7% on a sequential (QoQ) basis.
- EBITDA margins contracted to 27% in Q1 FY27, down from 31% in the previous quarter and 30% YoY.
- Human Nutrition segment revenue declined 7% YoY to ₹1,139 million, impacted by lower Pharma/API sales.
- Specialized Manufacturing segment grew 41% YoY to ₹200 million, now contributing 11% of total revenue.
- International sales increased to 51% of total revenue mix, with Europe and Asia (ex-India) growing 44% and 37% respectively.
Advanced Enzyme Technologies has approved a buyback of up to 13.94 lakh shares at a maximum price of ₹500 per share, representing a 54% premium to the current market price. The buyback size of ₹69.7 crore accounts for 5.09% of the consolidated net worth. Additionally, the company will acquire the remaining 4.28% stake in JC Biotech to make it a wholly-owned subsidiary and infuse ₹2 crore into Advanced Nutrazyme. These moves utilize the company's significant liquid surplus of ₹546 crore to simplify corporate structure and reward shareholders.
- Approved buyback of up to 1,394,000 equity shares at a maximum price of ₹500 per share via open market route
- Maximum buyback size of ₹69.7 crore represents 9.99% of standalone and 5.09% of consolidated net worth
- Acquisition of the remaining 4.28% stake in JC Biotech Private Limited to make it a 100% subsidiary
- Additional fund infusion of up to ₹20 million (₹2 crore) in Advanced Nutrazyme Private Limited
- Buyback price of ₹500 is a significant premium over the current market price of ₹324.4
Advanced Enzyme Technologies has approved a buyback of up to ₹69.7 crore via the open market route at a maximum price of ₹500 per share, a ~54% premium to the current price. The board also cleared the acquisition of the remaining 4.28% stake in JC Biotech Private Limited, making it a wholly-owned subsidiary. Additionally, a small capital infusion of ₹2 crore was approved for Advanced Nutrazyme. These moves utilize the company's strong cash position to consolidate holdings and return capital to shareholders.
- Maximum buyback size of ₹69.7 crore represents 9.99% of standalone paid-up capital and free reserves.
- Maximum buyback price set at ₹500 per share, significantly above the current market price of ₹324.4.
- Acquisition of the remaining 4.28% equity in JC Biotech Private Limited to achieve 100% ownership.
- Approved infusion of up to ₹20 million (₹2 crore) into wholly-owned subsidiary Advanced Nutrazyme Private Limited.
- Indicative maximum buyback of 1,394,000 equity shares, representing 1.24% of total paid-up capital.
Financial Performance
Revenue Growth by Segment
In Q2 FY26, the Human Nutrition segment grew 22% YoY to INR 1,212 million, while Animal Nutrition grew 6% YoY to INR 193 million. The Specialized Manufacturing segment showed the highest growth at 54% YoY, reaching INR 185 million. Overall consolidated revenue for Q2 FY26 grew 26% YoY to INR 1,845 million.
Geographic Revenue Split
For FY 2024-25, international sales accounted for 54% of revenue (up from 50% in FY 2023-24), while domestic sales contributed 46% (down from 50%). Exports, primarily to the US, represent approximately 48-49% of total revenue.
Profitability Margins
Profitability showed significant improvement in Q2 FY26 with PAT margins reaching 24% compared to 23% in Q2 FY25. For the full year FY 2024-25, operating margins were stable around 33-35%, benefiting from lower material and freight costs despite slower recovery in high-margin global markets.
EBITDA Margin
EBITDA margin for Q2 FY26 stood at 33%, a significant increase from 29% in Q2 FY25. This 400 basis point improvement was driven by a 42% YoY increase in absolute EBITDA to INR 601 million, reflecting strong operating leverage as revenue scaled.
Capital Expenditure
The company has planned a capital expenditure of INR 70-80 crore for setting up a new Research and Development (R&D) facility over the next three fiscals. This is expected to be funded entirely through internal accruals and existing liquid surplus of INR 546 crore.
Credit Rating & Borrowing
The company maintains a 'CRISIL A+/Stable' long-term rating and 'CRISIL A1' short-term rating. Borrowing is minimal with a gearing ratio of 0.03 times as of March 31, 2024. It has access to fund-based limits of INR 32.5 crore which remain marginally utilized.
Operational Drivers
Raw Materials
Specific raw material names are not listed, but the company utilizes inputs for fermentation and production of over 68 enzymes and probiotics. Material costs are a primary driver, with margins improving in FY24 due to lower material and freight expenses.
Capacity Expansion
Current total fermentation capacity is 500 cubic meters across 9 manufacturing facilities in India and the US. Expansion is currently focused on the Specialized Manufacturing segment where capacity utilization is increasing to support a 54% YoY revenue growth.
Raw Material Costs
Raw material and freight costs were lower in fiscal 2024, contributing to an increase in operating margin to 34% from 32% in fiscal 2023. The company uses technological innovation to mitigate inflationary pressures on these costs.
Manufacturing Efficiency
Operating efficiency is driven by integrated capabilities across the value chain, from R&D to distribution. The company operates 7 R&D centers to maintain its competitive edge in proprietary product development.
Logistics & Distribution
Distribution is handled through established channels in India and the US. Freight costs significantly impacted margins in FY23 (reducing them to 33%) but saw relief in FY24, aiding margin recovery.
Strategic Growth
Expected Growth Rate
15%
Growth Strategy
Growth will be achieved through a 15% CAGR revenue target by expanding the Specialized Manufacturing segment (currently 10% of revenue), increasing applications for enzymes and probiotics in Human Nutrition, and leveraging 7 R&D centers for new product development. The company also targets inorganic growth through acquisitions, supported by a liquid surplus of INR 546 crore.
Products & Services
The company sells over 400 proprietary products including enzymes, probiotics, bio-catalases, and specialized medicines like serratiopeptidase for human and animal nutrition.
Brand Portfolio
Advanced Enzymes, JC Biotech, Evoxx.
New Products/Services
The company is continuously developing new products from its basket of 68+ enzymes and probiotics, focusing on bio-catalysis and human healthcare applications to drive modest medium-term growth.
Market Expansion
Expansion is targeted in the Specialized Manufacturing segment and through deeper penetration in the US market, which currently accounts for nearly half of the consolidated revenue.
Market Share & Ranking
The company holds a robust market position in the global enzyme industry with a comprehensive product basket and significant fermentation capacity of 500 cubic meters.
Strategic Alliances
The company operates through key subsidiaries including JC Biotech (INR 186 million Q2 revenue) and Evoxx (INR 74 million Q2 revenue) to manage specialized segments and international operations.
External Factors
Industry Trends
The industry is seeing a rise in the application of enzymes, probiotics, and bio-catalases across human and animal nutrition. The company is positioning itself by expanding its specialized manufacturing and R&D capabilities to meet this growing demand.
Competitive Landscape
The company faces intense competition in the domestic market, particularly for products like serratiopeptidase, which keeps margins in the specialized manufacturing segment relatively low at 8-10%.
Competitive Moat
The moat is built on 400+ proprietary products, 7 R&D centers, and 9 manufacturing facilities. This technical expertise and integrated value chain make it difficult for competitors to replicate its specialized enzyme formulations.
Macro Economic Sensitivity
The company is sensitive to global demand shifts, particularly in the human nutrition segment which saw a revenue dip in H1FY25 due to lower demand and an INR 8 crore revenue reversal.
Consumer Behavior
There is a growing demand for probiotics and enzyme-based solutions in human healthcare, which the company is addressing through its largest segment, Human Nutrition (67% of sales).
Geopolitical Risks
Geopolitical turbulence is a risk to the supply chain and export demand, particularly for the 54% of revenue generated from international markets.
Regulatory & Governance
Industry Regulations
Operations are subject to stringent food and drug safety regulations globally. Compliance is critical as any failure could lead to product recalls or discontinuation of business by major customers.
Environmental Compliance
The company is committed to ESG principles to enhance stakeholder confidence and maintain access to capital markets, though specific INR compliance costs are not disclosed.
Taxation Policy Impact
The effective tax rate is approximately 28.5% based on FY25 consolidated figures (INR 534 million tax on INR 1,874 million PBT).
Risk Analysis
Key Uncertainties
Regulatory compliance risks and fluctuations in foreign exchange rates are the primary uncertainties. A significant adverse regulatory action could impact the business risk profile and lead to a rating downgrade if margins fall below 30%.
Geographic Concentration Risk
High geographic concentration in the US market, which accounts for approximately 48-49% of total revenue.
Third Party Dependencies
The company is actively reducing dependency on single suppliers to mitigate supply chain risks arising from geopolitical issues.
Technology Obsolescence Risk
The company mitigates technology risks through continuous R&D investment (INR 70-80 crore planned) and maintaining a portfolio of 400+ proprietary products.
Credit & Counterparty Risk
Receivables quality is generally high, supported by healthy relationships with customers, though the company maintains high working capital (197 days GCA) to support its US operations.
